Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients

Massimiliano Fabbiani; Simona Di Giambenedetto; Michela Sali; Salvatore Farina; Paola Sansonetti; Enrica Tamburrini; Lorenzo Zileri Dal Verme; Giovanni Delogu; Andrea De Luca; David Kelvin; Roberto Cauda; Giovanni Fadda

doi:10.1016/j.vaccine.2011.02.020

Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients

Massimiliano Fabbiani, Simona Di Giambenedetto, Michela Sali, Salvatore Farina, Paola Sansonetti, Enrica Tamburrini, Lorenzo Zileri Dal Verme, Giovanni Delogu, Andrea De Luca, David Kelvin, Roberto Cauda, Giovanni Fadda

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

31 Citas (Scopus)

Resumen

Immunogenicity of influenza A (H1N1)v MF59-adjuvanted vaccine was studied in HIV-infected patients. The vaccine was effective in inducing a protective immune response in patients with a CD4 >200. cells/μL while individuals with CD4 <200. cells/μL showed lower rates of seroconversion and seroprotection. These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients.

Idioma original	English
Páginas (desde-hasta)	2836-2839
Número de páginas	4
Publicación	Vaccine
Volumen	29
N.º	16
DOI	https://doi.org/10.1016/j.vaccine.2011.02.020
Estado	Published - abr. 5 2011
Publicado de forma externa	Sí

ASJC Scopus Subject Areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

PubMed: MeSH publication types

Journal Article

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1016/j.vaccine.2011.02.020

Otros archivos y enlaces

Citar esto

@article{67f8b98125ee49d082397925a51fee6a,

title = "Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients",

abstract = "Immunogenicity of influenza A (H1N1)v MF59-adjuvanted vaccine was studied in HIV-infected patients. The vaccine was effective in inducing a protective immune response in patients with a CD4 >200. cells/μL while individuals with CD4 <200. cells/μL showed lower rates of seroconversion and seroprotection. These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients.",

author = "Massimiliano Fabbiani and {Di Giambenedetto}, Simona and Michela Sali and Salvatore Farina and Paola Sansonetti and Enrica Tamburrini and Verme, {Lorenzo Zileri Dal} and Giovanni Delogu and {De Luca}, Andrea and David Kelvin and Roberto Cauda and Giovanni Fadda",

year = "2011",

month = apr,

day = "5",

doi = "10.1016/j.vaccine.2011.02.020",

language = "English",

volume = "29",

pages = "2836--2839",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "16",

}

TY - JOUR

T1 - Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients

AU - Fabbiani, Massimiliano

AU - Di Giambenedetto, Simona

AU - Sali, Michela

AU - Farina, Salvatore

AU - Sansonetti, Paola

AU - Tamburrini, Enrica

AU - Verme, Lorenzo Zileri Dal

AU - Delogu, Giovanni

AU - De Luca, Andrea

AU - Kelvin, David

AU - Cauda, Roberto

AU - Fadda, Giovanni

PY - 2011/4/5

Y1 - 2011/4/5

N2 - Immunogenicity of influenza A (H1N1)v MF59-adjuvanted vaccine was studied in HIV-infected patients. The vaccine was effective in inducing a protective immune response in patients with a CD4 >200. cells/μL while individuals with CD4 <200. cells/μL showed lower rates of seroconversion and seroprotection. These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients.

AB - Immunogenicity of influenza A (H1N1)v MF59-adjuvanted vaccine was studied in HIV-infected patients. The vaccine was effective in inducing a protective immune response in patients with a CD4 >200. cells/μL while individuals with CD4 <200. cells/μL showed lower rates of seroconversion and seroprotection. These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients.

UR - http://www.scopus.com/inward/record.url?scp=79953219744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953219744&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.02.020

DO - 10.1016/j.vaccine.2011.02.020

M3 - Article

C2 - 21349364

AN - SCOPUS:79953219744

SN - 0264-410X

VL - 29

SP - 2836

EP - 2839

JO - Vaccine

JF - Vaccine

IS - 16

ER -

Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients

Resumen

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto